Headache and Migraine

Migraine sufferers who are trying to cut back on alcoholic beverages in 2019 may find additional motivation for their New Year’s resolution.

A review of existing guidelines and principles for treating migraine released by the American Headache Society.

Results from the largest global survey of its kind reveals that migraine sufferers who have not responded to preventive treatment experience a substantial burden of disease.

This guide includes everything you need to know about erenumab-aooe (Aimovig, Amgen/Novartis) for the preventive treatment of migraine in adults.

The Clinical Director of the NHGRI spoke about the impact of the NIH program and its future development.

Neurology News Network for the week of January 5, 2019.

The position statement’s author noted that a lack of specificity in laws and inconsistencies in protocols has led to confusion surrounding brain death in several high-profile cases.

The program’s director spoke about its genesis and evolution into a more widespread initiative which has helped improve next-generation genome sequencing.

Some migraine sufferers who do not initially respond to galcanezumab may show clinically meaningful improvement if they stay on the drug for longer periods of time.

Neurology News Network for the week of December 22, 2018.

Patients treated with fremanezumab experienced highly significant reduction in the monthly average number of migraine days for both monthly and quarterly dosing regimens.

This brief year-end slideshow highlights significant progress in research into migraine, Alzheimer disease, stroke, multiple sclerosis, and autism.

Neurology News Network for the week of December 15, 2018.

The Senior Medical Director at Eli Lilly discussed the clinical impact galcanezumab could have for patients with cluster headache if approved by the FDA.

If you suspect vestibular migraine, you’re not alone. One in 10 patients receive the diagnosis that is often confused with other conditions.

Presenting our year in review, a collection by experts in their respective fields of brain injury, MS, concussion, epilepsy, migraine, and more.

Neurology News Network for the week of December 1, 2018.

The Senior Medical Director of Eli Lilly and Company spoke to lasmiditan and the clinical impact the investigational therapy could have for patients with acute migraine.

The non-invasive vagus nerve stimulator’s OK marks the first approval for cluster headache of any kind.

New research provides insights into migraine with visual aura, cognitive behavioral therapy, and the genetic basis of pediatric migraine.

A 20-year-old woman had a Caesarian section at 39 weeks. She had a history of migraine, but this headache was different. Her request for “something really strong” for the pain was cause for concern.

Neurology News Network for the week of November 24, 2018.

These findings are among the first in the United States to indicate an association between migraine and atrial fibrillation.

The director of the MedStar Georgetown University Hospital Headache Center shared her interest in the pipeline and the ongoing search for biomarkers in migraine.

The director of the MedStar Georgetown Headache Center discussed ways to improve the patient-provider relationship and how primary care can get involved.